Inactive Instrument
LYSOGENE Stock OTC Markets
Stocks
LYSGF
FR0013233475
Biotechnology & Medical Research
OTC Markets Traded
| 1 day | +45.23% |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 09/05/2014 | |
| Director of Finance/CFO | - | 01/11/2022 | |
Marie Trad
CTO | Chief Tech/Sci/R&D Officer | - | 01/02/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 54 | 22/05/2019 | |
Peter Lichtlen
BRD | Director/Board Member | 58 | 01/04/2018 |
Carole Deffez
BRD | Director/Board Member | - | 26/09/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +45.23% | +36.24% | - | - | 5.53M | |
| +0.67% | -5.95% | +123.78% | +99.25% | 4.44B | |
| -0.24% | -0.49% | +111.78% | +178.44% | 3.61B | |
| -1.94% | -12.32% | +62.88% | -33.26% | 2.19B | |
| -1.70% | +1.45% | -29.54% | -37.42% | 2.13B | |
| -0.91% | -6.40% | +182.06% | +223.25% | 1.88B | |
| +2.54% | -3.52% | +158.49% | -40.17% | 987M | |
| -7.09% | -1.50% | -13.10% | +15.16% | 875M | |
| +1.19% | -1.78% | -40.45% | -14.48% | 491M | |
| -4.01% | +7.57% | -1.41% | - | 468M | |
| Average | +3.40% | -0.59% | +61.61% | +48.85% | 1.9B | |
| Weighted average by Cap. | -0.66% | -1.24% | +87.51% | +79.37% |
Employees
22
